111 related articles for article (PubMed ID: 32763323)
21. Validation of a subclassification for high-risk prostate cancer in a prospective cohort.
Butler SS; Dee EC; Lamba N; Sha ST; Mahal BA; Whitbeck A; Makkar R; Wangoe J; Mouw KW; Nguyen PL; Muralidhar V
Cancer; 2020 May; 126(10):2132-2138. PubMed ID: 32073662
[TBL] [Abstract][Full Text] [Related]
22. Modified risk stratification grouping using standard clinical and biopsy information for patients undergoing radical prostatectomy: Results from SEARCH.
Zumsteg ZS; Chen Z; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Spratt DE; Sandler HM; Freedland SJ
Prostate; 2017 Dec; 77(16):1592-1600. PubMed ID: 28994485
[TBL] [Abstract][Full Text] [Related]
23. Heterogeneous oncologic outcomes according to surgical pathology in high-risk prostate cancer: implications for better risk stratification and preoperative prediction of oncologic outcomes.
Choi SK; Shim M; Kim M; Park M; Lee S; Song C; Lee HL; Ahn H
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1871-1878. PubMed ID: 28523407
[TBL] [Abstract][Full Text] [Related]
24. Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance.
Perlis N; Sayyid R; Evans A; Van Der Kwast T; Toi A; Finelli A; Kulkarni G; Hamilton R; Zlotta AR; Trachtenberg J; Ghai S; Fleshner NE
J Urol; 2017 Jan; 197(1):75-83. PubMed ID: 27457260
[TBL] [Abstract][Full Text] [Related]
25. Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer.
Yang DD; Mahal BA; Muralidhar V; Nezolosky MD; Vastola ME; Labe SA; Boldbaatar N; King MT; Martin NE; Orio PF; Beard CJ; Hoffman KE; Trinh QD; Spratt DE; Feng FY; Nguyen PL
Eur Urol Focus; 2019 Jan; 5(1):69-76. PubMed ID: 28753811
[TBL] [Abstract][Full Text] [Related]
26. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy.
Klein EA; Yousefi K; Haddad Z; Choeurng V; Buerki C; Stephenson AJ; Li J; Kattan MW; Magi-Galluzzi C; Davicioni E
Eur Urol; 2015 Apr; 67(4):778-86. PubMed ID: 25466945
[TBL] [Abstract][Full Text] [Related]
27. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
28. The impact of pretreatment PSA on risk stratification in men with Gleason 6 prostate cancer: Implications for active surveillance.
Monfared S; Fleishman A; Korets R; Chang P; Wagner A; Bubley G; Kaplan I; Olumi AF; Gershman B
Urol Oncol; 2021 Nov; 39(11):783.e21-783.e30. PubMed ID: 33992521
[TBL] [Abstract][Full Text] [Related]
29. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
[TBL] [Abstract][Full Text] [Related]
30. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
31. Unfavorable Intermediate-Risk Prostate Cancer and the Odds of Upgrading to Gleason 8 or Higher at Prostatectomy.
Martin NE; Chen MH; Zhang D; Richie JP; D'Amico AV
Clin Genitourin Cancer; 2017 Apr; 15(2):237-241. PubMed ID: 27426058
[TBL] [Abstract][Full Text] [Related]
32. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers.
Sundi D; Tosoian JJ; Nyame YA; Alam R; Achim M; Reichard CA; Li J; Wilkins L; Schwen Z; Han M; Davis JW; Klein EA; Schaeffer EM; Stephenson AJ; Ross AE; Chapin BF
Cancer; 2019 Feb; 125(3):391-397. PubMed ID: 30423193
[TBL] [Abstract][Full Text] [Related]
34. Robot-assisted laparoscopic radical prostatectomy in patients with prostate cancer with high-risk features: predictors of favorable pathologic outcome.
Uberoi J; Brison D; Patel N; Sawczuk IS; Munver R
J Endourol; 2010 Mar; 24(3):403-7. PubMed ID: 20078237
[TBL] [Abstract][Full Text] [Related]
35. Preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomy.
Pierorazio PM; Lin BM; Mullins JK; Hyndman ME; Schaeffer EM; Han M; Partin AW; Pavlovich CP
Urol Oncol; 2013 Jul; 31(5):589-94. PubMed ID: 21664838
[TBL] [Abstract][Full Text] [Related]
36. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
[TBL] [Abstract][Full Text] [Related]
37. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery.
Tosoian JJ; Sundi D; Trock BJ; Landis P; Epstein JI; Schaeffer EM; Carter HB; Mamawala M
Eur Urol; 2016 Apr; 69(4):576-581. PubMed ID: 26456680
[TBL] [Abstract][Full Text] [Related]
38. Role of radical prostatectomy in patients with prostate cancer of high Gleason score.
Tefilli MV; Gheiler EL; Tiguert R; Banerjee M; Sakr W; Grignon D; Wood DP; Pontes JE
Prostate; 1999 Apr; 39(1):60-6. PubMed ID: 10221268
[TBL] [Abstract][Full Text] [Related]
39. Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.
Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
Int J Clin Oncol; 2015 Feb; 20(1):176-81. PubMed ID: 24771079
[TBL] [Abstract][Full Text] [Related]
40. Postoperative upgrading of prostate cancer in men ≥75 years: a propensity score-matched analysis.
Herlemann A; Buchner A; Kretschmer A; Apfelbeck M; Stief CG; Gratzke C; Tritschler S
World J Urol; 2017 Oct; 35(10):1517-1524. PubMed ID: 28493044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
